Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643742 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
A Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 7
- Study locations
NCT05643742: Recruiting Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, sponsored by CRISPR Therapeutics.
NCT05643742 is a Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 120 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05643742, a Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Conditions Studied
Interventions
- BIOLOGICAL CTX112
Study Locations (7)
Kansas
- University of Kansas - Westwood
Missouri
- Washington University - St Louis
Texas
- SCRI - San Antonio
Utah
- University of Utah - Salt Lake City
New South Wales
- Royal Prince Alfred - Camperdown
Victoria
- Alfred Health - Melbourne
Western Australia
- Sir Charles Gairdner Hospital - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2030-02 |
| Phase | Phase 1 |
What NCT05643742 shows while recruiting
NCT05643742 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower).
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CTX112 is the first listed.
NCT05643742 lists 7 locations in 7 states (Kansas, Missouri, Texas).
Frequently Asked Questions
What is clinical trial NCT05643742 about?
NCT05643742 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies". This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
What is the current status of trial NCT05643742?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-03-10. Estimated completion is 2030-02.
What conditions does trial NCT05643742 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT05643742?
The interventions under investigation include: CTX112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05643742?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05643742 being conducted?
This trial has 7 study locations across Kansas, Missouri, Texas, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05643742's enrollment target sits among peer trials
120 31st of 106 higher than 75 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI